SLC 391
Alternative Names: SLC-0211; SLC-391; XZB-0004Latest Information Update: 28 Feb 2025
At a glance
- Originator SignalChem Lifesciences
- Developer Merck & Co; SignalChem Lifesciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
- No development reported Acute myeloid leukaemia; COVID 2019 infections; Solid tumours
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in Canada (PO)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Monotherapy) in Canada (PO)
- 28 Feb 2025 No recent reports of development identified for phase-I development in COVID-2019-infections in Canada (PO)